Bridging the Translational Gap in Nanoparticle-Based Drug Delivery Systems: Formulation Strategies, Safety, Scalability and Clinical Perspectives

Nanoparticle-based drug delivery has become an active area of pharmaceutical research because it offers ways to address some of the limitations of conventional dosage forms. Depending on how they are designed, nanoparticles may help improve the apparent solubility or stability of a drug, protect it from degradation, and alter where and how quickly it is released in the body. Researchers have explored several platforms, including liposomes, polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, metallic nanoparticles, and lipid nanoparticles. These systems have been studied for conditions such as cancer, infectious diseases, and neurological disorders. Even so, encouraging laboratory results do not always lead to successful medicines. Challenges can arise when a formulation is moved from a small laboratory process to industrial production, or when it encounters the complexity of the human body. This review looks at formulation and characterization methods, biological safety, biodistribution, manufacturing scale-up, quality-by-design, regulatory expectations, and clinical applications. It also considers approaches that may make nanoparticle products more consistent and more suitable for clinical use. Progress will depend on treating formulation, safety, manufacturing, and clinical evaluation as connected parts of the same development process